Intraperitoneal and systemic chemotherap
β
Vaughn, Clarence B. ;Chapman, Janet L. ;Herschman, Barry R. ;Bonczak, Michael J.
π
Article
π
1990
π
John Wiley and Sons
π
English
β 414 KB
## Abstract Five to ten percent of patients with adenocarcinoma of the endometrium present with advanced disease [1] or develop metastasis and require systemic therapy for control of disease. About oneβthird (33%) of recurrent or advanced endometrial cancer responds to progestational agents [2β4].